Clinical transplantation tolerance twelve years after prospective withdrawal of immunosuppressive drugs: Studies of chimerism and anti-donor reactivity

Transplantation

Volumn 69, Issue 8, 2000, Pages 1549-1554

  Strober, Samuel ^a,b   Benike, Claudia ^a   Krishnaswamy, Shalini ^a   Engleman, Edgar G ^a   Grumet, F Carl ^a  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b STANFORD UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HLA A ANTIGEN; HLA ANTIBODY; HLA B ANTIGEN; HLA DR ANTIGEN; PREDNISONE; THYMOCYTE ANTIBODY;

ADULT; ALLOGRAFT; ARTICLE; CADAVER DONOR; CASE REPORT; CHIMERA; CLONAL ANERGY; CONTROLLED STUDY; FOLLOW UP; GRAFT REJECTION; HLA MATCHING; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOLOGICAL TOLERANCE; KIDNEY TRANSPLANTATION; LYMPH NODE IRRADIATION; PRIORITY JOURNAL;

EID: 0034720063     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/00007890-200004270-00005     Document Type: Article

References (29)

1. Induction of specific unresponsiveness to heart allografts in mongrel dogs treated with total lymphoid irradiation and anti-thymocyte globulin
2. Mixed allogeneic chimerism and renal allograft tolerance in cynomolgus monkeys
3. Promotion of incompatible allograft acceptance in rhesus monkeys given posttransplant antithymocyte globulin and donor bone marrow. I. In vivo parameters and immunohistologic evidence suggesting microchimerism
4. The development of a posttransplant TLI treatment strategy that promotes organ allograft acceptance without chronic immunosuppression
5. Peritransplant tolerance induction with anti-CD3-immunotoxin
6. Acquired immune tolerance to cadaveric renal allografts
7. Chimerism and donor-specific non-reactivity 27 to 29 years after kidney allotransplantation
8. The lost chord: Microchimerism and allograft survival
9. Microchimerism, dendritic cell progenitors and transplantation tolerance
10. Treatment of cadaveric renal transplant recipients with total lymphoid irradiation, anti-thymocyte globulin and low dose prednisone
11. Clinical and immunological studies of cadaveric renal transplant recipients given total lymphoid irradiation (TLI) and maintained on low dose prednisone
12. Polymorphism of adhesion molecule CD31 and its role in acute graft vs. host disease
13. Cell migration, chimerism and graft acceptance
14. Microchimerism linked to cytotoxic T lymphocyte functional unresponsiveness (clonal allergy) in a tolerant renal transplant recipient
15. Peripheral microchimerism in long-term cadaveric kidney allograft recipients
16. Donor-recipient microchimerism is not required for tolerance induction following recipient pretreatment with donor-specific transfusion and anti-CD4 antibody
17. Preclinical studies of allograft tolerance in rhesus monkeys: A novel anti-CD3-Immunotoxin given peritransplant with donor bone marrow induces operational tolerance to kidney allografts
18. Male fetal progenitor cells persist in maternal blood for as long as 27 years postpartum
19. Microchimerism of maternal origin persists into adult life
20. Survival of donor leukocyte subpopulations in immunocompetent transfusion recipients: Frequent long-term microchimerism in severe trauma patients
21. Indirect Allorecognition of major histocompatibility complex allopeptides in human renal transplant recipients with chronic graft dysfunction
22. Assessment of the contribution that direct allorecognition makes to the progression of chronic cardiac transplant rejection in humans
23. Cell-mediated lympholysis studies in renal allograft recipients
24. CD4 monoclonal antibody pairs for immunosuppression and tolerance induction
25. Mediation of skin allograft rejection in SCID mice by CD4+ and CD8+ T cells
26. Mechanisms in anti-CD4 antibody-mediated transplantation tolerance: Kinetics of induction, antigen dependency and role of regulatory T cells
27. Increased expression of IL-4 and IL-10 and decreased expression of IL-2 and interferon-γ in long-surviving mouse heart allografts after brief CD4 monoclonal antibody therapy
28. Posttransplant antidonor lymphocytotoxic antibody production in relation to graft outcome